Showing 1821-1830 of 4063 results for "".
- Roche Files for FDA Emergency Use Authorization for SARS-CoV-2 Rapid Antigen Testhttps://modernod.com/news/roche-files-for-fda-emergency-use-authorization-for-sars-cov-2-rapid-antigen-test/2478844/Roche announced it has submitted for FDA Emergency Use Authorization (EUA) for a SARS-CoV-2 Rapid Antigen Test that is designed for use by health care professionals in point-of-care settings with patients experiencing symptoms of COVID-19. The test is designed to help health care professi
- JCRS Publishes Phase 2 Nepafenac Clinical Trial With Evolute Sustained Drug Delivery Systemhttps://modernod.com/news/jcrs-publishes-phase-2-nepafenac-clinical-trial-with-evolute-sustained-drug-delivery-system/2478843/Mati Therapeutics announced that a peer reviewed manuscript of a phase 2 clinical trial evaluating the safety and efficacy of Nepafenac delivered via Mati’s proprietary Evolute sustained ocular drug delivery platform has been published in the February Journal of Cataract and Refractive Surgery
- Surface Ophthalmics Announces First Patient Dosed in Phase 2 Trial for SURF-200 for Acute Dry Eyehttps://modernod.com/news/surface-ophthalmics-announces-first-patient-dosed-in-phase-2-trial-for-surf-200-for-acute-dry-eye/2478833/Surface Ophthalmics announced that the first patient has been dosed in the phase 2 clinical trial for its investigational product SURF-200 (betamethasone in Klarity vehicle) for the treatment of acute dry eye. In this dose-ranging study, SURF-200 will be studied in two different low concen
- Ocuphire Completes Enrollment in MIRA-2 Phase 3 Clinical Trial Investigating Nyxol for Reversal of Mydriasishttps://modernod.com/news/ocuphire-completes-enrollment-in-mira-2-phase-3-clinical-trial-investigating-nyxol-for-reversal-of-mydriasis/2478719/Ocuphire Pharma announced that it has completed enrollment earlier than expected in its MIRA-2 phase 3 registration clinical trial evaluating the safety and efficacy of Nyxol to reverse pharmacologically-induced mydriasis. “We are pleased to exceed our enrollment target and reach this impo
- Azura Ophthalmics Announces Primary Endpoints Met in Phase 2 Trial of Investigational Treatment for Contact Lens Discomforthttps://modernod.com/news/azura-ophthalmics-announces-primary-endpoints-met-in-phase-2-trial-of-investigational-treatment-for-contact-lens-discomfort/2478686/Azura Ophthalmics announced topline results from a phase 2 clinical trial evaluating the company’s investigational therapy for the treatment of contact lens discomfort (CLD). The ECLIPTIC study examining Azura’s lead asset, AZR-MD-001, met its primary endpoints by showing statistically significan
- Regenxbio Announces Dosing of First Patient in Phase 2 ALTITUDE Trial of RGX-314 for the Treatment of DRhttps://modernod.com/news/regenxbio-announces-dosing-of-first-patient-in-phase-2-altitude-trial-of-rgx-314-for-the-treatment-of-dr/2478651/Regenxbio announced that the first patient has been dosed in ALTITUDE, a phase 2 trial to evaluate the suprachoroidal delivery of RGX-314 using the SCS Microinjector for the treatment of diabetic retinopathy (DR). “We are pleased to announce the first patient dosed in our ALTITUDE tr
- Gyroscope Therapeutics Announces First Patient Dosed in Phase 2 Trial Evaluating Investigational Gene Therapy for Dry AMDhttps://modernod.com/news/gyroscope-therapeutics-announces-first-patient-dosed-in-phase-2-trial-evaluating-investigational-gene-therapy-for-dry-amd/2478523/Gyroscope Therapeutics announced the initiation of the phase 2 HORIZON trial evaluating GT005 in people with geographic atrophy (GA) secondary to dry age-related macular degeneration (AMD). The first patient to receive GT005 in HORIZON was enrolled and dosed in the United States by Jeff
- Oculis Announces Presentation of Positive Results From Phase 2 Trial of OCS-01 in Patients With Diabetic Macular Edema (DME)https://modernod.com/news/oculis-announces-presentation-of-positive-results-from-phase-2-trial-of-ocs-01-in-patients-with-diabetic-macular-edema-dme/2478362/Oculis announced that the positive results from the successful phase 2 (DX-211) clinical trial investigating OCS-01 for the treatment of diabetic macular edema (DME) were presented at Euretina 2020 Virtual during the Late Breaking & Reviews session on October 3. OCS-01 is a novel, high
- Ocular Therapeutix Announces First Patients Dosed in Phase 2 Clinical Trial of OTX-CSI for the Treatment of Dry Eye Diseasehttps://modernod.com/news/ocular-therapeutix-announces-first-patients-dosed-in-phase-2-clinical-trial-of-otx-csi-for-the-treatment-of-dry-eye-disease/2478343/Ocular Therapeutix announced that it has dosed the first patients in its hase 2 clinical trial of OTX-CSI (cyclosporine intracanalicular insert) for the treatment of dry eye disease. “Having successfully completed the phase 1 study, we are excited to have recently begun dosing patients in
- Aurinia Completes Final Patient Treatment in AUDREY Phase 2/3 Clinical Trial of Voclosporin Ophthalmic Solution for Dry Eyehttps://modernod.com/news/aurinia-completes-final-patient-treatment-in-audrey-phase-2-3-clinical-trial-of-voclosporin-ophthalmic-solution-for-dry-eye/2478336/Aurinia Pharmaceuticals announced that the last patient study visit has occurred in the phase 2/3 AUDREY clinical study evaluating voclosporin ophthalmic solution (VOS) for the potential treatment of dry eye syndrome (DES). “Despite the challenges posed by the ongoing viral pandemic, our c